首页> 美国卫生研究院文献>Experimental and Therapeutic Medicine >Exogenous pulmonary surfactant for acute respiratory distress syndrome in adults: A systematic review and meta-analysis
【2h】

Exogenous pulmonary surfactant for acute respiratory distress syndrome in adults: A systematic review and meta-analysis

机译:成人急性呼吸窘迫综合征的外源性肺表面活性物质:系统评价和荟萃分析

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Acute respiratory distress syndrome (ARDS) is often characterized by reduced lung compliance, which suggests dysfunction of the endogenous surfactant system. The effectiveness of exogenous surfactants as replacements for the endogenous system in the treatment of ARDS in adults was assessed. Randomized controlled trials from Medline (1950–2011), Embase (1989–2011), the Cochrane Database of Systematic Reviews and the Cochrane Central Register of Controlled Trials (1994–2011) were analyzed. Two reviewers identified trials for inclusion and the results of included trials were quantitatively pooled with a fixed-effects model. Seven trials (2,144 patients) with good methodological quality were included in the analysis. Pulmonary surfactant treatment was not associated with reduced mortality [relative risk (RR), 1.00; 95% confidence interval (CI) 0.89–1.12]. Subgroup analysis revealed no reduced mortality for various surfactant types. Heterogeneity was not significant in the primary outcome analysis (I2=0%). There was no evidence of publication bias. Oxygenation, ventilation-free days, duration of ventilation and APACHE II scores did not undergo pooled analysis due to insufficient data. Exogenous surfactant did not reduce mortality in adults with ARDS in our meta-analysis, and we cannot accurately define whether exogenous surfactant has an effect on oxygenation from the included studies.
机译:急性呼吸窘迫综合征(ARDS)通常以降低的肺顺应性为特征,这表明内源性表面活性剂系统功能异常。评估了外源性表面活性剂替代内源性系统治疗成人ARDS的有效性。分析了Medline(1950–2011),Embase(1989–2011),Cochrane系统评价数据库和Cochrane对照试验中央注册簿(1994–2011)的随机对照试验。两名审稿人确定了纳入试验,并使用固定效应模型将合并试验的结果定量合并。分析包括7项方法学质量良好的试验(2,144例患者)。肺表面活性剂治疗与死亡率降低无关[相对危险度(RR),1.00; 95%置信区间(CI)0.89–1.12]。亚组分析表明,各种表面活性剂类型的死亡率均未降低。主要结果分析中异质性不显着(I 2 = 0%)。没有证据表明出版物有偏见。由于数据不足,未对氧合,无呼吸天数,呼吸持续时间和APACHE II评分进行汇总分析。在我们的荟萃分析中,外源性表面活性剂并未降低ARDS成年人的死亡率,我们无法从纳入的研究中准确定义外源性表面活性剂是否对氧合有影响。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号